prostatic-like syndrome in a woman with chronic lymphocytic leukemia: sequential kinase inhibitor therapy
Clicks: 119
ID: 235855
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.3
/100
119 views
32 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #45 of 57 articles by views in Turkish journal of haematology : official journal of Turkish Society of Haematology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Chronic lymphocytic leukemia (CLL) is an incurable lymphoproliferative disorder with a heterogeneous genetic and clinical course. Two kinase inhibitors, ibrutinib and idelalisib, have demonstrated achievement of complete and durable remissions in relapse/refractory genetically unselected CLL patients. We present a case of relapsed CLL with extensive disease and hourglass deformity of urinary bladder as a result of the compression of two extraperitoneal paravesical soft tissue bulky masses, with excellent response to sequential kinase inhibitor therapy.
| Reference Key |
velasco-rodrguez2017caseprostatic-like
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Diego Velasco-Rodríguez;Miguel Piris-Villaespesa;Carmen Soteras;Ana Vallés;José Antonio García-Marco;José Antonio García-Vela |
| Journal | Turkish journal of haematology : official journal of Turkish Society of Haematology |
| Year | 2017 |
| DOI |
10.1155/2017/3869020
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.